Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–5 of 5 results
Advanced filters: Author: "Fadi Fakhouri" Clear advanced filters

  • Effective treatments for atypical haemolytic uraemic syndrome (aHUS) have long been lacking, but the discovery that complement dysregulation is a major risk factor for this disease and the availability of the complement inhibitor eculizumab have improved the clinical picture. Legendre et al. have now published results from two prospective trials investigating eculizumab use in aHUS. Although we have come a long way, questions remain.

    • Fadi Fakhouri
    • Véronique Frémeaux-Bacchi
    News & Views
    Nature Reviews Nephrology
    Volume: 9, P: 495-496

  • Several distinct pathological patterns of glomerular disorders are associated with abnormal regulation of the complement system. Some of these conditions are characterized by glomerular deposits of complement C3 in the absence or in the presence of marginal deposits of immunoglobulin. In this Perspectives article, the authors suggest that glomerular pathologies where isolated complement C3 deposition is found should be classified by the term 'C3 glomerulopathy'.

    • Fadi Fakhouri
    • Véronique Frémeaux-Bacchi
    • Matthew C. Pickering
    Reviews
    Nature Reviews Nephrology
    Volume: 6, P: 494-499

  • The difficulties that are inherent in the differential diagnosis of hemolytic uremic syndrome and thrombotic thrombocytopenic purpura are a function of the overlap in presenting features. The authors of this Review assert that patient management could be more usefully directed by basing diagnosis on recently elucidated pathogenic mechanisms. To that end, they discuss the involvement of deficiencies in metalloprotease ADAMTS13, and dysfunctional complement proteins.

    • Fadi Fakhouri
    • Véronique Frémeaux-Bacchi
    Reviews
    Nature Clinical Practice Nephrology
    Volume: 3, P: 679-687

  • Knowledge of complement genetics has improved understanding of the pathogenesis of primary atypical haemolytic uraemic syndrome (aHUS). This Review summarizes current knowledge of complement genetics in aHUS and discusses how complement studies affect the management of patients with other thrombotic microangiopathies.

    • Fadi Fakhouri
    • Véronique Frémeaux-Bacchi
    Reviews
    Nature Reviews Nephrology
    Volume: 17, P: 543-553

  • Here, Zuber et al., on behalf of the French Study Group for aHUS/C3G, discuss the role of eculizumab in the treatment of atypical haemolytic uraemic syndrome (aHUS). They review data from case reports and preliminary data from prospective trials, present their opinions, and describe issues that require further study. In addition, they discuss the potential use of eculizumab in C3 glomerulopathies.

    • Julien Zuber
    • Fadi Fakhouri
    • Véronique Frémeaux-Bacchi
    Reviews
    Nature Reviews Nephrology
    Volume: 8, P: 643-657